# Piramal Pharma (PPLPHARMA) — Stock analysis

> Faxioms all-in-one stock review. Canonical page: https://faxioms.com/stocks/pplpharma

## Current market snapshot

- Exchange: NSE
- Country: India
- Price: ₹238.92
- Change: +0.12%
- As of: 2026-11-06
- 1D return: +0.12%
- 5D return: +0.00%
- 1M return: +21.63%
- Latest complete quarter: fy27_q2

## Faxioms Analysis

_As of 2026-11-06_

### Technical Outlook

PPLPHARMA is trading at ₹238.92, positioned near the upper end of its recent ranges (+92.6% in the 20-day and 50-day windows; +96.1% in the 252-day window). The technical structure is uniformly bullish across daily, weekly, and monthly timeframes, with price holding above all supplied moving averages and the Supertrend indicator. Trend strength is established on the daily (ADX 33.37) and weekly (ADX 32.54) charts, and strong on the monthly chart (ADX 40.34), supported by positive DI readings (+DI > -DI) on daily and weekly horizons.

Participation has been intense recently, marked by extreme volume anomalies on 2026-10-28 (volume ratio 50.8) and 2026-10-30 (volume ratio 5.95) accompanying significant upward price moves. However, the stock faces immediate resistance just above current levels, with the nearest high at ₹239.32 (0.17% away) and subsequent barriers at ₹241.12 and ₹243.60. Recent candlestick formations, including a Harami on 2026-11-04 and a Bearish Engulfing Reversal on 2026-11-03, suggest short-term consolidation or profit-taking pressure despite the broader uptrend. Volatility remains elevated (annualized volatility +38.3%, ATR 3.77%), and the stock is currently 7.5% below its available high.

The setup confirms continuation if price sustains above the pivot support at ₹238.78 and breaks through ₹239.32 with volume. Invalidation would occur if price closes decisively below key moving averages or the Supertrend, particularly if it falls below the ₹236.30 low support.

- Trend: Bullish across all timeframes; price above all MAs and Supertrend. ADX indicates established (daily/weekly) to strong (monthly) trend conviction.
- Levels: Immediate resistance at ₹239.32 (+0.17%) and ₹241.12 (+0.92%). Pivot support at ₹238.78 (-0.06%); next major low support at ₹236.30 (-1.10%).
- Momentum & Participation: Extreme volume spikes observed on 2026-10-28 and 2026-10-30. Recent bearish reversal patterns (Harami, Bearish Engulfing) signal short-term caution near highs.
- Risk: High volatility (ATR 3.77%, annualized vol +38.3%). Stock is +96.1% into its 252-day range, implying limited upside buffer before historical highs.

- Harami
- Bearish Engulfing Reversal
- Bullish Engulfing Reversal
- Outside Bar
- Doji

### Official Filings

Piramal Pharma Limited (NSE: PPLPHARMA) reported unaudited financial results for the quarter and half-year ended September 30, 2026, on October 27, 2026. The company delivered consolidated revenue growth of 28% year-over-year in Q2 FY27 and 23% in H1 FY27, driven by strong performance across its Contract Development and Manufacturing Organization (CDMO), Complex Hospital Generics (CHG), and Consumer Healthcare (PCH) segments. EBITDA increased 72% year-on-year in both periods, with margins expanding by over 350 basis points due to higher capacity utilization and operating leverage.

Management upgraded its full-year FY27 outlook, now expecting revenue growth of 19% to 20% with meaningfully higher profitability. Operational highlights included the addition of 22 new CDMO customers, successful integration of the Kenalog® acquisition into CHG revenues, and a 51% year-over-year increase in ADC services revenues. The company also completed 110 customer audits and 12 regulatory inspections during H1 FY27. An analyst conference call was held on October 28, 2026, with transcripts and recordings made available. Further institutional investor meetings are scheduled for November 17 and 18, 2026.

- Q2 FY27 consolidated revenue grew 28% year-over-year; H1 FY27 revenue grew 23%, with EBITDA up 72% in both periods.
- EBITDA margins expanded by over 350 basis points, attributed to higher capacity utilization and operating leverage.
- Full-year FY27 outlook upgraded to 19%-20% revenue growth with meaningfully higher profitability.
- Operational momentum includes 22 new CDMO customers, 51% YoY growth in ADC services, and Kenalog® integration.

- [PIRAMAL PHARMA LIMITED has informed the Exchange about Transcripts - earnings or quarterly calls |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_20978_WebXMLFile_20261030_150441511.xml)
- [Piramal Pharma Limited has informed the Exchange about Transcript |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/Priyankamehta_30102026153649_SEIntimationAnalystcallTranscript.pdf)
- [Intimation of Schedule of Institutional Investor Meetings under the SEBI LODR Regulations, 2015 |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/PIRAMALPHARMA_30102026161332_SEIntimation_Investor_call.pdf)
- [Piramal Pharma Limited has informed the Exchange about Schedule of Analysts or Institutional Investors Meet |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_20978_WebXMLFile_20261030_162100986.xml)
- [PIRAMAL PHARMA LIMITED has informed the Exchange about Audio Recording/Video Recording |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_20978_WebXMLFile_20261028_164828711.xml)
- [Piramal Pharma Limited has informed the Exchange about Link of Recording |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/Priyankamehta_28102026171720_Outcomeofinvestorcall_audio.pdf)
- [Piramal Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. |SUBJECT: Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/Priyankamehta_27102026210048_Outcome_of_BM_271026.pdf)
- [Piramal Pharma Limited has informed the Exchange about Investor Presentation |SUBJECT: Investor Presentation](https://nsearchives.nseindia.com/corporate/Priyankamehta_27102026210533_PRandIRIntimation27Oct26sd.pdf)
- [Piramal Pharma Limited has informed the Exchange regarding a press release dated October 27, 2026, titled "Piramal Pharma Limited Announces Results for Q2 and H1 FY2". |SUBJECT: Press Release](https://nsearchives.nseindia.com/corporate/Priyankamehta_27102026210401_PRandIRIntimation27Oct26sd.pdf)
- [Piramal Pharma Limited has informed the Exchange about Presentation |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/Priyankamehta_27102026210719_PRandIRIntimation27Oct26sd.pdf)

### Fundamentals

Piramal Pharma (PPLPHARMA) demonstrated a sharp operational recovery in Q2 FY2026-27, with revenue from operations rising sequentially to ₹2,617 crore and net profit turning positive at ₹5.03 crore, compared to a ₹69.4 crore loss in Q1. This turnaround was driven by strong year-on-year sales growth of 28.05% and an operating profit increase to ₹348.74 crore. However, earnings quality remains under pressure; the TTM compounded profit growth is -81%, and the TTM EPS is negative (-₹1.57). The balance sheet shows total assets growing to ₹18,537 crore, supported by higher borrowings (₹5,873 crore as of Sep 2026) and fixed assets (₹9,483 crore), while cash reserves increased to ₹545 crore. Notably, FIIs reduced their stake significantly to 13.65% in Sep 2026, down from 30.27% the prior year, indicating shifting institutional sentiment despite improved quarterly results.

- Q2 FY2026-27 Net Profit turned positive at ₹5.03 crore, reversing a Q1 loss of ₹69.4 crore, driven by a 28.05% YoY sales jump to ₹2,617 crore.
- TTM profitability remains weak with -81% compounded profit growth and negative EPS (-₹1.57), highlighting a divergence between recent quarterly improvement and longer-term trends.
- Total borrowings rose to ₹5,873 crore (Sep 2026) alongside fixed asset expansion to ₹9,483 crore, signaling continued capital deployment.
- FIIs exited substantially, reducing holdings from 30.27% (Sep 2025) to 13.65% (Sep 2026), while promoters maintained ~34.8% ownership.

### Bull Case

Piramal Pharma (PPLPHARMA) demonstrates strong technical momentum and sector tailwinds that support a constructive interpretation, despite recent volatility. As of November 6, 2026, the stock trades at ₹238.92, with Supertrend indicators signaling a bullish trend across daily, weekly, and monthly timeframes. The company has benefited from the broader pharmaceutical sector's outperformance in 2026, which saw the sectoral index rise 27% year-to-date driven by resilient domestic demand and improving US business margins. Piramal Pharma shares surged over 20% alongside peers like Laurus Labs, contributing to a robust +40.6% year-to-date return and a +44.6% return over the past six months. While the stock faces near-term resistance levels between ₹239.32 and ₹241.12, the underlying technical structure remains positive, supported by an Average Directional Index (ADX) above 30 on daily and weekly charts, indicating strong trend strength. Investors should monitor whether the stock can sustainably break above immediate resistance zones while managing annualized volatility of 38.3%.

- Technical Trend Strength: Supertrend indicators are bullish across daily, weekly, and monthly timeframes as of November 6, 2026, with ADX values of 33.37 (daily), 32.54 (weekly), and 40.34 (monthly), confirming strong directional momentum.
- Sector Tailwinds: India’s pharmaceutical sector is the best-performing equity segment in 2026, up 27% year-to-date, driven by resilient domestic demand and improving US margins; Piramal Pharma surged 20% alongside peers.
- Performance Metrics: The stock delivers a +40.6% YTD return and +44.6% return over the last six months, trading at ₹238.92 with a market capitalization of approximately ₹31,770 crore.
- Key Levels to Watch: Immediate resistance lies at ₹239.32 (+0.17%) and ₹241.12 (+0.92%), while support is anchored at ₹238.78 (-0.06%) and ₹236.30 (-1.10%).

- [Pills are paying off! Pharma stocks lead 2026 rally with up to 112% return](https://economictimes.indiatimes.com/markets/stocks/news/pills-are-paying-off-pharma-stocks-lead-2026-rally-with-up-to-112-return/articleshow/135561757.cms)
- [Broader markets outperform; Ather Energy, Piramal Pharma, Laurus Labs surge over 20% each](https://www.moneycontrol.com/news/business/markets/broader-markets-outperform-ather-energy-piramal-pharma-laurus-labs-surge-over-20-each-14065365.html)
- [PIRAMAL PHARMA LIMITED has informed the Exchange about Transcripts - earnings or quarterly calls |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_20978_WebXMLFile_20261030_150441511.xml)
- [Piramal Pharma Limited has informed the Exchange about Transcript |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/Priyankamehta_30102026153649_SEIntimationAnalystcallTranscript.pdf)
- [Intimation of Schedule of Institutional Investor Meetings under the SEBI LODR Regulations, 2015 |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/PIRAMALPHARMA_30102026161332_SEIntimation_Investor_call.pdf)
- [Piramal Pharma Limited has informed the Exchange about Schedule of Analysts or Institutional Investors Meet |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_20978_WebXMLFile_20261030_162100986.xml)
- [PIRAMAL PHARMA LIMITED has informed the Exchange about Audio Recording/Video Recording |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_20978_WebXMLFile_20261028_164828711.xml)
- [Piramal Pharma Limited has informed the Exchange about Link of Recording |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/Priyankamehta_28102026171720_Outcomeofinvestorcall_audio.pdf)
- [Piramal Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. |SUBJECT: Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/Priyankamehta_27102026210048_Outcome_of_BM_271026.pdf)
- [Piramal Pharma Limited has informed the Exchange about Investor Presentation |SUBJECT: Investor Presentation](https://nsearchives.nseindia.com/corporate/Priyankamehta_27102026210533_PRandIRIntimation27Oct26sd.pdf)

### Bear Case

Piramal Pharma (PPLPHARMA) faces elevated volatility and significant historical drawdown risk despite recent price strength. As of November 6, 2026, the stock trades at ₹238.92 with an annualized volatility of +38.3% and a downside deviation of +22.9%, indicating substantial price fluctuation that can impact retail portfolios. The stock has experienced a maximum drawdown of -48.4% historically, and currently sits in a -7.5% drawdown from its peak, suggesting persistent sensitivity to market corrections. While the sectoral rally has driven a +40.6% year-to-date return and a +19.2% one-month gain, analysts caution that valuations may limit further market-beating gains compared to other sectors. Immediate technical resistance is tight, with the nearest level at ₹239.32 (0.17% above), potentially capping short-term upside momentum.

- High Volatility: Annualized volatility stands at +38.3% with a downside deviation of +22.9%, exposing investors to significant price swings.
- Drawdown Risk: The stock carries a maximum historical drawdown of -48.4% and is currently -7.5% below its recent high.
- Valuation Caution: Sector analysts note that current valuations may restrict further outperformance relative to broader market benchmarks.
- Technical Resistance: Immediate overhead pressure exists at ₹239.32, just 0.17% above the current close of ₹238.92.

- [Pills are paying off! Pharma stocks lead 2026 rally with up to 112% return](https://economictimes.indiatimes.com/markets/stocks/news/pills-are-paying-off-pharma-stocks-lead-2026-rally-with-up-to-112-return/articleshow/135561757.cms)
- [Broader markets outperform; Ather Energy, Piramal Pharma, Laurus Labs surge over 20% each](https://www.moneycontrol.com/news/business/markets/broader-markets-outperform-ather-energy-piramal-pharma-laurus-labs-surge-over-20-each-14065365.html)
- [PIRAMAL PHARMA LIMITED has informed the Exchange about Transcripts - earnings or quarterly calls |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_20978_WebXMLFile_20261030_150441511.xml)
- [Piramal Pharma Limited has informed the Exchange about Transcript |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/Priyankamehta_30102026153649_SEIntimationAnalystcallTranscript.pdf)
- [Intimation of Schedule of Institutional Investor Meetings under the SEBI LODR Regulations, 2015 |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/PIRAMALPHARMA_30102026161332_SEIntimation_Investor_call.pdf)
- [Piramal Pharma Limited has informed the Exchange about Schedule of Analysts or Institutional Investors Meet |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_20978_WebXMLFile_20261030_162100986.xml)
- [PIRAMAL PHARMA LIMITED has informed the Exchange about Audio Recording/Video Recording |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_20978_WebXMLFile_20261028_164828711.xml)
- [Piramal Pharma Limited has informed the Exchange about Link of Recording |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/Priyankamehta_28102026171720_Outcomeofinvestorcall_audio.pdf)
- [Piramal Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. |SUBJECT: Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/Priyankamehta_27102026210048_Outcome_of_BM_271026.pdf)
- [Piramal Pharma Limited has informed the Exchange about Investor Presentation |SUBJECT: Investor Presentation](https://nsearchives.nseindia.com/corporate/Priyankamehta_27102026210533_PRandIRIntimation27Oct26sd.pdf)

### FAQs

**What recent price performance and market context should investors be aware of for Piramal Pharma?**

Piramal Pharma shares surged over 20% alongside broader market outperformance, contributing to a sector-wide rally where pharma stocks led 2026 gains with up to 112% returns for some peers. As of November 6, 2026, the stock closed at ₹238.92 on the NSE, reflecting strong momentum within an industry driven by resilient domestic demand and improving US business margins.

**What are the key technical levels and trend indicators for the stock as of November 6, 2026?**

The daily Supertrend is bullish, with immediate resistance at ₹239.32 (0.17% above) and support at ₹238.78 (0.06% below). The stock has gained +40.6% year-to-date and +44.6% over six months, though it faces a maximum historical drawdown of -48.4%. Annualized volatility stands at +38.3%, indicating significant price fluctuation risk despite the current upward trajectory.

**What upcoming events or filings might influence investor sentiment in the near term?**

Piramal Pharma has scheduled physical institutional investor meetings in Mumbai on November 17, 2026 (arranged by Avendus Spark) and November 18, 2026 (arranged by JM Financial Service). These group meetings follow the October 28, 2026 conference call regarding Unaudited Financial Results for the quarter ended September 30, 2026. Investors should monitor these dates for potential updates on operational performance.

- [Pills are paying off! Pharma stocks lead 2026 rally with up to 112% return](https://economictimes.indiatimes.com/markets/stocks/news/pills-are-paying-off-pharma-stocks-lead-2026-rally-with-up-to-112-return/articleshow/135561757.cms)
- [Broader markets outperform; Ather Energy, Piramal Pharma, Laurus Labs surge over 20% each](https://www.moneycontrol.com/news/business/markets/broader-markets-outperform-ather-energy-piramal-pharma-laurus-labs-surge-over-20-each-14065365.html)
- [PIRAMAL PHARMA LIMITED has informed the Exchange about Transcripts - earnings or quarterly calls |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_20978_WebXMLFile_20261030_150441511.xml)
- [Piramal Pharma Limited has informed the Exchange about Transcript |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/Priyankamehta_30102026153649_SEIntimationAnalystcallTranscript.pdf)
- [Intimation of Schedule of Institutional Investor Meetings under the SEBI LODR Regulations, 2015 |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/PIRAMALPHARMA_30102026161332_SEIntimation_Investor_call.pdf)
- [Piramal Pharma Limited has informed the Exchange about Schedule of Analysts or Institutional Investors Meet |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_20978_WebXMLFile_20261030_162100986.xml)
- [PIRAMAL PHARMA LIMITED has informed the Exchange about Audio Recording/Video Recording |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_20978_WebXMLFile_20261028_164828711.xml)
- [Piramal Pharma Limited has informed the Exchange about Link of Recording |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/Priyankamehta_28102026171720_Outcomeofinvestorcall_audio.pdf)
- [Piramal Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. |SUBJECT: Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/Priyankamehta_27102026210048_Outcome_of_BM_271026.pdf)
- [Piramal Pharma Limited has informed the Exchange about Investor Presentation |SUBJECT: Investor Presentation](https://nsearchives.nseindia.com/corporate/Priyankamehta_27102026210533_PRandIRIntimation27Oct26sd.pdf)
## Technical analytics

- As of: 2026-11-06
- Daily trend: Strong Uptrend
- Weekly trend: Moderate Uptrend
- Pivot point: ₹238.78
- Risk regime: Higher Price Risk

### Support levels
- 239.325
- 215.905
- 210.5

### Resistance levels
- 244.1
- 251.95
- 241.11666666666667

### Return and range metrics

| Metric | Value |
| --- | --- |
| return_1 | +0.12% |
| return_10 | +25.04% |
| return_1m | +19.15% |
| return_1y | +19.86% |
| return_20 | +21.63% |
| return_3m | +14.73% |
| return_5 | +0.00% |
| return_6m | +44.63% |
| return_since_start | -7.48% |
| return_ytd | +40.64% |

### Risk and volatility metrics

| Metric | Value |
| --- | --- |
| state | high_risk |
| label | Higher price risk |
| summary | Recent drawdown or price variability is materially high and may lead to larger short-term outcomes. |
| maximum_drawdown | -48.39% |
| annualized_volatility | +38.28% |

## Quarterly financials

- Latest complete quarter: fy27_q2

# Piramal Pharma Limited Q2 FY2026-27: Revenue up 15% QoQ; profit for the period turns positive

Consolidated revenue from operations rose 15.3% quarter on quarter to ₹2,617 crore in Q2 FY2026-27, while profit for the period was ₹5.03 crore, compared with a ₹69.39 crore loss in Q1. The quarter still had a ₹12.71 crore loss from continuing operations, and cash and cash equivalents declined to ₹545 crore from ₹1,200 crore at 31 March 2026.

## Revenue recovery and expenses

Revenue increased from ₹2,270 crore in Q1 FY2026-27 and ₹2,044 crore in Q2 FY2025-26. The latest quarter remained below the ₹2,752 crore reported in Q4 FY2025-26, the highest in the recent quarterly series.

Total expenses rose 8.5% sequentially to ₹2,589 crore, below revenue growth of 15.3%. Other expenses increased 18.5% to ₹648 crore, while finance costs edged down to ₹87.6 crore from ₹88.1 crore in Q1. The combination of higher revenue and slower growth in total expenses accompanied the improvement in pre-tax results.

## Profitability and tax

Profit before tax was ₹63.89 crore, versus a loss of ₹27.02 crore in Q1 FY2026-27 and a loss of ₹60.97 crore in Q2 FY2025-26. Tax expense rose to ₹76.60 crore from ₹61.93 crore in the previous quarter, leaving a ₹12.71 crore loss from continuing operations.

A ₹17.74 crore share of profit from associates and joint ventures accounted for using the equity method contributed to the ₹5.03 crore profit for the period. Basic and diluted EPS from continuing operations were ₹0.04, compared with a loss of ₹0.52 per share in Q1.

## Cash, investment and borrowings

Cash and cash equivalents stood at ₹545 crore on 30 September 2026, down from ₹1,200 crore on 31 March 2026. Over the same dates, property, plant and equipment increased to ₹4,496 crore from ₹4,451 crore, and capital work in progress rose to ₹966 crore from ₹799 crore.

Noncurrent borrowings increased to ₹4,454 crore from ₹4,300 crore, while current borrowings were ₹1,212 crore, compared with ₹1,196 crore. Inventories rose to ₹3,295 crore from ₹3,064 crore and trade receivables to ₹2,254 crore from ₹2,158 crore. These movements make liquidity and the funding of investment important areas to monitor.

## Key Takeaway

Piramal Pharma’s sequential revenue and pre-tax recovery brought the company to a small profit for the period, supported by its equity-method contribution. The continuing-operations loss and lower cash balance temper the improvement, while higher work in progress, inventories and borrowings keep cash conversion and investment funding in focus.

### Ratios

## Shareholding pattern

- Quarter: FY2027-Q1
- As of: 2026-06-30
- Promoter holding: +34.80%
- FII holding: +12.51%
- DII holding: +14.57%
- Mutual fund holding: +13.18%
- Retail holding: +11.02%
- Promoter pledged: +0.00%

### Major reported shareholders

- The Sri Krishna Trust (through its Trustee Mr. Ajay G Piramal and Dr. (Mrs.) Swati A. Piramal) — +26.51% (Trusts)
- CA Alchemy Investments — +17.93%
- Hdfc Trustee Company Limited-Hdfc Flexi Cap Fund — +7.68%
- V3 Designs LLP — +3.23% (Bodies Corporate)
- PRL Realtors LLP — +2.99% (Bodies Corporate)
- East Bridge Capital Master Fund I Ltd — +2.00%
- Indiahold Limited — +1.30% (Overseas Corporate Bodies)
- Piramal Welfare Trust — +0.79% (Trusts)
- Semplice Corporate Solutions Private Limited (Formerly known as AASAN Corporate Solutions Private Limited) — +0.67% (Bodies Corporate)
- The Ajay G. Piramal Foundation — +0.33% (Trusts)

## Official filings

- 2026-10-30 — Generic Announcement: Piramal Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_20978_WebXMLFile_20261030_150441511.xml)
- 2026-10-30 — Generic Announcement: Piramal Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/Priyankamehta_30102026153649_SEIntimationAnalystcallTranscript.pdf)
- 2026-10-30 — Generic Announcement: Piramal Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/PIRAMALPHARMA_30102026161332_SEIntimation_Investor_call.pdf)
- 2026-10-30 — Generic Announcement: Piramal Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_20978_WebXMLFile_20261030_162100986.xml)
- 2026-10-28 — Generic Announcement: Piramal Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_20978_WebXMLFile_20261028_164828711.xml)
- 2026-10-28 — Generic Announcement: Piramal Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/Priyankamehta_28102026171720_Outcomeofinvestorcall_audio.pdf)
- 2026-10-27 — Generic Announcement: Piramal Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/Priyankamehta_27102026210048_Outcome_of_BM_271026.pdf)
- 2026-10-27 — Earnings Presentation: Piramal Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/Priyankamehta_27102026210533_PRandIRIntimation27Oct26sd.pdf)
- 2026-10-27 — Press Release: Piramal Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/Priyankamehta_27102026210401_PRandIRIntimation27Oct26sd.pdf)
- 2026-10-27 — Generic Announcement: Piramal Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/Priyankamehta_27102026210719_PRandIRIntimation27Oct26sd.pdf)
- 2026-10-27 — Financial Results Filing: Piramal Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1747272_27102026091408_WEB.xml)
- 2026-10-27 — Financial Results Filing: Piramal Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1747277_27102026091803_WEB.xml)
- 2026-10-21 — Shareholding Disclosure: Piramal Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SHP_1742857_21102026032628_WEB.xml)
- 2026-10-16 — Board Meeting Notice: Piramal Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/Priyankamehta_16102026122148_PriorBMIntimation27102026.pdf)
- 2026-10-16 — Generic Announcement: Piramal Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/Priyankamehta_16102026122625_AnalystCall_Initimation28102026.pdf)
- 2026-10-16 — Generic Announcement: Piramal Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_20978_WebXMLFile_20261016_122846999.xml)
- 2026-10-16 — Board Meeting Notice: Piramal Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_20978_WebXMLFile_20261016_122846999.xml)
- 2026-10-16 — Generic Announcement: Piramal Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_20978_WebXMLFile_20261016_123325382.xml)
- 2026-10-01 — Generic Announcement: Piramal Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/PIRAMALPHARMA_01102026105231_Responseletter.pdf)
- 2026-10-01 — Generic Announcement: Piramal Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/PIRAMALPHARMA_01102026201104_SERegulation30Intimation.pdf)
- 2026-09-30 — Generic Announcement: Piramal Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/content/RSS/Online_announcements.xml)
- 2026-09-30 — Generic Announcement: Piramal Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/PIRAMALPHARMA_30092026175952_SE_IntimationRetirementandAppointmentofSMP.pdf)
- 2026-09-30 — Generic Announcement: Piramal Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/CIM_20978_WebXMLFile_20260930_180510491.xml)
- 2026-09-30 — Management Change: Piramal Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/PIRAMALPHARMA_30092026201259_SEIntimationAppointmentofCTO.pdf)
- 2026-09-30 — Generic Announcement: Piramal Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/CIM_20978_WebXMLFile_20260930_201909147.xml)

## News and market events

- 2026-11-05 — Economic Times: **Pills are paying off! Pharma stocks lead 2026 rally with up to 112% return** — India's pharmaceutical sector has emerged as the best-performing equity segment in 2026, with the sectoral index rising 27% year-to-date and leading stocks like Laurus Labs delivering returns of up to 112%. This outperformance is attributed to resilient domestic demand, improving US business margins, and new product opportunities such as semaglutide, which have supported an underlying earnings recovery. While analysts view the rally as sustainable due to predictable earnings, some caution that valuations may limit further market-beating gains compared to other sectors. — [Source](https://economictimes.indiatimes.com/markets/stocks/news/pills-are-paying-off-pharma-stocks-lead-2026-rally-with-up-to-112-return/articleshow/135561757.cms)
- 2026-11-01 — MONEYCONTROL: **Broader markets outperform; Ather Energy, Piramal Pharma, Laurus Labs surge over 20% each** — Shares of Ather Energy, Piramal Pharma, and Laurus Labs surged by more than 20% each, contributing to broader market outperformance. — [Source](https://www.moneycontrol.com/news/business/markets/broader-markets-outperform-ather-energy-piramal-pharma-laurus-labs-surge-over-20-each-14065365.html)
- 2026-10-29 — MONEYCONTROL: **Buy Piramal Pharma; target of Rs 290: ICICI Securities** — ICICI Securities has issued a 'Buy' recommendation for Piramal Pharma with a price target of Rs 290. — [Source](https://www.moneycontrol.com/news/business/buy-piramal-pharma-target-of-rs-290-icici-securities-14063495.html)
- 2026-10-29 — MONEYCONTROL: **Buy Piramal Pharma; target of Rs 270: Motilal Oswal** — Motilal Oswal has issued a 'Buy' recommendation for Piramal Pharma with a price target of Rs 270. — [Source](https://www.moneycontrol.com/news/business/buy-piramal-pharma-target-of-rs-270-motilal-oswal-14063389.html)
- 2026-10-28 — MONEYCONTROL: **Piramal Pharma surges 18% to 18-month high as Q2 results beat estimates; brokerage upgrades to Add, check target price** — Piramal Pharma surges 18% to 18-month high as Q2 results beat estimates; brokerage upgrades to Add, check target price Follow Us On: Stocks: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z Others Trending Topics more Sensex Today Jio Platforms Share Price Jio IPO Listing Price Cyclone Arnab Live Gold Price Akash Ambani Karnataka MLC Polls Israel exit polls HUL Q2 Results Prashant Kishor News more Business Markets Stocks India News City News Economy Mutual Funds Personal Finance IPO News Startups Markets more Home Currencies Commodities Pre-Market IPO Global Market US Markets Bonds Silver M — [Source](https://www.moneycontrol.com/news/business/markets/piramal-pharma-surges-18-to-18-month-high-as-q2-results-beat-estimates-brokerage-upgrades-to-add-check-target-price-14062631.html)
- 2026-10-28 — The Hindu: **Piramal Pharma looks to a ‘significantly stronger’ second half of the year: Nandini Piramal** — Piramal Pharma raises 19-20% growth guidance and targets a stronger H2 amid robust orders, market gains, and a stable outlook. — [Source](https://www.thehindubusinessline.com/companies/piramal-pharma-looks-to-a-significantly-stronger-second-half-of-the-year-nandini-piramal/article71635055.ece)
- 2026-10-28 — CNBC-TV18: **Piramal Pharma shares surge 14% as Q2 profitability improves, FY27 outlook raised** — Following its strong first-half performance and sustained business momentum, Piramal Pharma upgraded its FY27 revenue growth outlook to 19%-20%. The company also expects meaningfully higher profitability. — [Source](https://www.cnbctv18.com/market/piramal-pharma-share-price-surges-q2-profitability-improves-fy27-outlook-raised-20021020.htm)
- 2026-10-28 — MONEYCONTROL: **Buzzing Stocks: L&T gains 5% on 33% jump in Q2 profit; Piramal Pharma surges 12% as it turns profitable** — Buzzing Stocks: L&T gains 5% on 33% jump in Q2 profit; Piramal Pharma surges 12% as it turns profitable Follow Us On: Stocks: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z Others Trending Topics more Sensex Today Jio Platforms Share Price Jio IPO Listing Date Israel Elections 2026 live Microsoft Buyout news Gyanesh Kumar Benjamin Netanyahu Noel Tata Ather Share Price Anthropic IPO News more Business Markets Stocks India News City News Economy Mutual Funds Personal Finance IPO News Startups Markets more Home Currencies Commodities Pre-Market IPO Global Market US Markets Bonds Silver MCX P — [Source](https://www.moneycontrol.com/news/business/markets/buzzing-stocks-l-t-gains-5-on-33-jump-in-q2-profit-piramal-pharma-surges-12-as-it-turns-profitable-14061720.html)
- 2026-10-28 — CNBC-TV18: **ICICI Securities sees telecom among Nifty's biggest sectors as tariff hike nears** — Pankaj Pandey, Head of Retail Research at ICICI Securities, expects another 16-20% telecom tariff hike to improve 5G monetisation and cash flows, while limited competition could support long-term growth. The brokerage also highlighted Radico Khaitan's premiumisation strategy and Piramal Pharma's expanding CDMO business as key investment themes. Disclaimer: The views and tips expressed by investment experts on CNBCTV18.com are their own, not of the website or its management. CNBCTV18.com advises users to check with certified experts before taking any investment decisions. — [Source](https://www.cnbctv18.com/videos/market/icici-securities-telecom-tariff-hike-radico-khaitan-piramal-pharma-pankaj-pandey-20020993.htm)
- 2026-10-28 — The Hindu: **Piramal Pharma Limited Announces Results for Q2 and H1 FY27** — MUMBAI, India , Oct. — [Source](https://www.thehindubusinessline.com/brandhub/pr-release/piramal-pharma-limited-announces-results-for-q2-and-h1-fy27/article71634145.ece)
- 2026-10-27 — The Hindu: **Piramal Pharma Q2 results: Company swings to ₹5 crore profit** — Piramal Pharma reports a ₹5 crore Q2 profit against a year-ago loss of ₹99.22 crore as revenue rises to ₹2,617.06 crore and shares close 1.69% higher. — [Source](https://www.thehindubusinessline.com/companies/piramal-pharma-swings-to-5-crore-profit-in-q2-as-revenue-rises-28/article71633222.ece)
- 2026-10-27 — CNBC-TV18: **Stocks to Watch for October 28: Jio Platforms, TATA Capital, Infosys, AWL Agri and more** — From Tata Capital, AWL Agri Business and Vedanta Iron & Steel reporting their Q2 results to Jio Platforms making its market debut tomorrow, here are the stocks to watch in Wednesday’s trading session. — [Source](https://www.cnbctv18.com/photos/market/stocks-to-watch-for-october-28-jio-platforms-listing-price-tata-capital-infosys-awl-agri-and-more-20020516.htm)
- 2026-10-27 — CNBC-TV18: **Piramal Pharma Q2 Results: Firm swings to profit as revenue jumps 28%, led by CDMO growth** — Piramal Pharma swung to a net profit of ₹5.58 crore in Q2 FY27 from a loss of ₹99.2 crore a year earlier, as revenue grew 28% to ₹2,617 crore and EBITDA margin expanded to 13.3%. The company upgraded its FY27 revenue growth outlook to 19%–20%, supported by first-half business momentum and improved profitability. — [Source](https://www.cnbctv18.com/market/stocks/piramal-pharma-share-price-q2-results-firm-swings-to-profit-as-revenue-jumps-28-led-by-cdmo-growth-20020757.htm)
- 2026-10-16 — MONEYCONTROL: **Piramal Pharma bets on complex peptides, ADCs as rivals expand into GLP-1 drugs** — Piramal Pharma, Piramal Pharma peptides, Piramal Pharma adcs — [Source](https://www.moneycontrol.com/news/business/piramal-pharma-bets-on-complex-peptides-adcs-as-rivals-expand-into-glp-1-drugs-14053987.html)
- 2026-10-06 — The Hindu: **/C O R R E C T I O N -- Piramal Pharma Solutions/** — /C O R R E C T I O N -- Piramal Pharma Solutions/ — [Source](https://www.thehindu.com/brandhub/pr-release/c-o-r-r-e-c-t-i-o-n-piramal-pharma-solutions/article71550724.ece)
- 2026-10-06 — The Hindu: **Piramal Pharma Solutions Launches New Microbiology Laboratory at Its Lexington, KY Sterile Injectable Facility** — Piramal Pharma Solutions Launches New Microbiology Laboratory at Its Lexington, KY Sterile Injectable Facility — [Source](https://www.thehindubusinessline.com/brandhub/pr-release/piramal-pharma-solutions-launches-new-microbiology-laboratory-at-its-lexington-ky-sterile-injectable-facility/article71550553.ece)
- 2026-10-05 — BUSINESSTODAY: **Holding pharma stocks? Minor correction offers buying opportunity, says analyst** — pharma stocks, Indian pharma sector, Kranti Batini, Edelweiss Securities, pharma rally, healthcare stocks, hospital stocks, buy pharma on dips, term investment, long term investment, Cipla news, Sun Pharma update, Piramal Pharma news, Aurobindo Pharma news, Indian stock market sectors, defensive sectors India, pharma market outlook, healthcare sector outlook, stock market correction, sectoral investment strategy — [Source](https://www.businesstoday.in/markets/stocks/story/holding-pharma-stocks-minor-correction-is-a-buying-opportunity-says-bathini-559556-2026-10-05)
- 2026-09-30 — The Hindu: **Piramal Pharma Solutions and NP2 to Complete Cyclophosphamide Development Phase Next Month** — Piramal Pharma Solutions and NP2 to Complete Cyclophosphamide Development Phase Next Month — [Source](https://www.thehindubusinessline.com/brandhub/pr-release/piramal-pharma-solutions-and-np2-to-complete-cyclophosphamide-development-phase-next-month/article71529193.ece)
- 2026-09-30 — The Hindu: **Piramal Pharma Solutions and NP2 to Complete Cyclophosphamide Development Phase Next Month** — Piramal Pharma Solutions and NP2 to Complete Cyclophosphamide Development Phase Next Month — [Source](https://www.thehindu.com/brandhub/pr-release/piramal-pharma-solutions-and-np2-to-complete-cyclophosphamide-development-phase-next-month/article71529188.ece)
- 2026-09-30 — The Hindu: **Ontario Contributes $1.7 Million Investment to Advance Life Sciences Innovation at Piramal Pharma's Aurora Facility** — Ontario Contributes $1.7 Million Investment to Advance Life Sciences Innovation at Piramal Pharma's Aurora Facility — [Source](https://www.thehindubusinessline.com/brandhub/pr-release/ontario-contributes-17-million-investment-to-advance-life-sciences-innovation-at-piramal-pharmas-aurora-facility/article71526588.ece)
- 2026-09-30 — The Hindu: **Ontario Contributes $1.7 Million Investment to Advance Life Sciences Innovation at Piramal Pharma's Aurora Facility** — Ontario Contributes $1.7 Million Investment to Advance Life Sciences Innovation at Piramal Pharma's Aurora Facility — [Source](https://www.thehindu.com/brandhub/pr-release/ontario-contributes-17-million-investment-to-advance-life-sciences-innovation-at-piramal-pharmas-aurora-facility/article71526583.ece)
- 2026-09-16 — The Hindu: **Piramal Pharma Solutions Advances Sustainability Efforts with Solar Power Plant Addition at Morpeth, UK Site** — Piramal Pharma Solutions Advances Sustainability Efforts with Solar Power Plant Addition at Morpeth, UK Site — [Source](https://www.thehindu.com/brandhub/pr-release/piramal-pharma-solutions-advances-sustainability-efforts-with-solar-power-plant-addition-at-morpeth-uk-site/article71473374.ece)
- 2026-09-16 — BUSINESS: **Piramal Pharma Ltd drops for fifth straight session** — Piramal Pharma Ltd is quoting at Rs 202.53, down 0.46% on the day as on 13:19 IST on the NSE. The stock  in last one year as compared to a 8.14%  in NIFTY and a 17.48%  lost  in the Nifty Pharma index. — [Source](https://www.business-standard.com/markets/capital-market-news/piramal-pharma-ltd-drops-for-fifth-straight-session-126091600629_1.html)
- 2026-09-15 — CNBC-TV18: **Piramal Pharma shares fall 3% after USFDA issues 7 observations at UK facility** — The USFDA issued a Form 483 following a Good Manufacturing Practices (GMP) inspection of the facility, Piramal Pharma said in a stock exchange filing on Monday. — [Source](https://www.cnbctv18.com/market/piramal-pharma-share-price-fall-usfda-form-483-morpeth-uk-facility-gmp-inspection-7-observations-19990884.htm)
- 2026-09-14 — The Hindu: **Piramal Pharma Morpeth facility gets 7 US FDA observations** — Piramal Pharma’s Morpeth facility in the UK received 7 US FDA observations after an inspection from September 3-11, 2026. The company will respond. — [Source](https://www.thehindubusinessline.com/companies/piramal-pharmas-uk-facility-receives-7-observations-from-us-fda-inspection/article71466358.ece)

## Business profile

**Strategic vision:** Global pharmaceutical company advancing healthcare through products and services.

### Business segments
- **Piramal Pharma Solutions:** Piramal Pharma Solutions operates as a Contract Development and Manufacturing Organization (CDMO) providing end-to-end development and manufacturing solutions across the drug lifecycle.
- **Piramal Critical Care:** Piramal Critical Care is a global provider of inhaled anesthetics and hospital generics, focusing on delivering critical care products to healthcare systems.
- **Piramal Consumer Healthcare:** Piramal Consumer Healthcare is a significant player in the Indian self-care market, offering a portfolio of branded consumer healthcare and wellness products.
- **AbbVie Therapeutics India Private Limited:** This joint venture is active in the ophthalmic category in India, providing medications and devices for various eye conditions.

### Competitive strengths
- Globally integrated network of facilities
- Science-led innovation
- Adherence to global quality and regulatory standards
- Diverse portfolio of products and services

## Related stocks

- [Abbott India Limited (Healthcare)](https://faxioms.com/stocks/abbotindia) — -0.85%
- [Ajanta Pharma Limited (Healthcare)](https://faxioms.com/stocks/ajantpharm) — +0.55%
- [Alkem Laboratories Limited (Healthcare)](https://faxioms.com/stocks/alkem) — +2.06%
- [Biocon Limited (Healthcare)](https://faxioms.com/stocks/biocon) — +0.86%
- [Gland Pharma Limited (Healthcare)](https://faxioms.com/stocks/gland) — +0.78%

## Freshness and sources

- Data as of: 2026-11-06
- Source: Faxioms public stock analysis API

Canonical: https://faxioms.com/stocks/pplpharma
Markdown representation: https://faxioms.com/stocks/pplpharma?render=md